Regulatory T cell: A protection for tumour cells

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 3, 2012, Pages 425-436

  Wang, Yi ^a   Ma, Yushui ^a   Fang, Ying ^a   Wu, Shengdi ^a   Liu, Lili ^a   Fu, Da ^a   Shen, Xizhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Foxp3; IL 10; TGF ; Tregs

Indexed keywords

INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METASTASIS; NATURAL KILLER CELL; NEOPLASM; PATHOLOGY; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-10; KILLER CELLS, NATURAL; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALIA;

EID: 84863116473     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01437.x     Document Type: Article

References (118)

1. Gershon RK, Hencin R, Liebhabe SAet al, Suppressor T cells. J Immunol. 1972; 108: 586-90.
2. Sakaguchi S, Sakaguchi N, Asano Met al., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155: 1151-64.
3. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. Nat Immunol. 2003; 4: 330-6.
4. Rifa'i M, Kawamoto Y, Nakashima Iet al., Essential roles of CD8(+)CD122(+) regulatory T cells in the maintenance of T cell homeostasis. J Exp Med. 2004; 200: 1123-34.
5. Maul J, Loddenkemper C, Mundt Pet al., Peripheral and intestinal regulatory CD4+CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005; 128: 1868-78.
6. Valencia X, Yarboro C, Illei Get al., Deficient CD4(+)CD25(high) T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007; 178: 2579-88.
7. Viglietta V, Baecher-Allan C, Weiner HLet al., Loss of functional suppression by CD4(+)CD25(+) regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199: 971-9.
8. Xu DP, Fu JL, Jin Let al., Circulating and liver resident CD4(+)CD25(+) regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B-1. J Immunol. 2006; 177: 739-47.
9. Bates GJ, Fox SB, Han Cet al., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24: 5373-80.
10. Gao Q, Qiu SJ, Fan Jet al., Intratumoural balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25: 2586-93.
11. Salama P, Phillips M, Grieu Fet al., Tumour-infiltrating FOXP3(+) T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009; 27: 186-92.
12. Sinicrope FA, Rego RL, Ansell SMet al., Intraepithelial effector (CD3(+))/regulatory (FoxP3(+)) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009; 137: 1270-9.
13. Tan W, Zhang W, Strasner Aet al., Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011; 470: 548-53.
14. Dieckmann D, Plottner H, Berchtold Set al., Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001; 193: 1303-10.
15. Jonuleit H, Schmitt E, Kakirman Het al., Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med. 2002; 196: 255-60.
16. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008; 8: 523-32.
17. Shimizu J, Yamazaki S, Takahashi Tet al., Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002; 3: 135-42.
18. Takahashi T, Tagami T, Yamazaki Set al., Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000; 192: 303-9.
19. Zhang M, Volpert O, Shi YHet al., Maspin is an angiogenesis inhibitor. Nat Med. 2000; 6: 196-9.
20. Luo JL, Tan W, Ricono JMet al., Nuclear cytokine-activated IKK alpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007; 446: 690-4.
21. Massague J TGF beta in cancer. Cell. 2008; 134: 215-30.
22. Li MO, Wan YY, Sanjabi Set al., Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006; 24: 99-146.
23. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002; 2: 46-53.
24. Ralainirina N, Poli A, Michel Tet al., Control of NK cell functions by CD4(+) CD25(+) regulatory T cells. J Leukocyte Biol. 2007; 81: 144-53.
25. Cederbom L, Hall H, Ivars F. CD4(+)CD25(+) regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000; 30: 1538-43.
26. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol. 1998; 160: 1589-97.
27. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001; 194: 629-44.
28. Lai CF, Ripperger J, Morella KKet al., Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem. 1996; 271: 13968-75.
29. Uhlig HH, Coombes J, Mottet Cet al., Characterization of Foxp3(+)CD4(+)CD25(+) and IL-10-secreting CD4(+)CD25(+) T cells during cure of colitis. J Immunol. 2006; 177: 5852-60.
30. Dercamp C, Chemin K, Caux Cet al., Distinct and overlapping roles of interleukin-10 and CD25(+) regulatory T cells in the inhibition of antitumour CD8 T-cell responses. Cancer Res. 2005; 65: 8479-86.
31. Strauss L, Bergmann C, Szczepanski Met al., A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumour microenvironment. Clin Cancer Res. 2007; 1: 4345-54.
32. Araki M, Chung D, Liu Set al., Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 Type 1 diabetes region in nonobese diabetic mice. J Immunol. 2009; 183: 5146-57.
33. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000; 192: 295-302.
34. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996; 183: 2541-50.
35. Greenwald RJ, Oosterwegel MA, van der Woude Det al., CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol. 2002; 32: 366-73.
36. Tivol EA, Borriello F, Schweitzer ANet al., Loss of CTLA-4 leads to massive lymphoprolireation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3: 541-7.
37. Bachmann MF, Kohler G, Ecabert Bet al., Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol. 1999; 163: 1128-31.
38. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4)-a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007; 110: 2614-27.
39. Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surgl Oncol. 2008; 15: 3014-21.
40. Kohm AP, Williams JS, Miller SD. Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4(+) T cell activation and experimental autoimmune encephalomyelitis. J Immunol. 2004; 172: 4686-90.
41. Morris GP, Kong YCM. Interference with CD4(+) CD25(+) T-cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody. J Autoimmun. 2006; 26: 24-31.
42. Ko K, Yamazaki S, Nakamura Ket al., Treatment of advanced tumours with agonistic anti-GITR mAb and its effects on tumour-infiltrating Foxp3(+)CD25(+)CD4(+) regulatory T cells. J Exp Med. 2005; 202: 885-91.
43. Ronchetti S, Zollo O, Bruscoli Set al., GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol. 2004; 34: 613-22.
44. Collison LW, Pillai MR, Chaturvedi Vet al., Regulatory T cell suppression is potentiated by target t cells in a cell contact, IL-35-and IL-10-dependent manner. J Immunol. 2009; 182: 6121-8.
45. Collison LW, Workman CJ, Kuo TTet al., The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450: 566-619.
46. Collison LW, Chaturvedi V, Henderson ALet al., IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010; 11: 1093-101.
47. Deaglio S, Dwyer KM, Gao Wet al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204: 1257-65.
48. Borsellino G, Kleinewietfeld M, Di Mitri Det al., Expression of ectonucleotidase CD39 by Foxp3(+) Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110: 1225-32.
49. Gondek DC, Lu LF, Quezada SAet al., Cutting edge: contact-mediated suppression by CD4(+)-CD25(+) regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005; 174: 1783-6.
50. Grossman WJ, Verbsky JW, Barchet Wet al., Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004; 21: 589-601.
51. Pandiyan P, Zheng LX, Ishihara Set al., CD4(+) CD25(+) Foxp3(+) regulatory T cells induce cytokine deprivation mediated apoptosis of effector CD4(+) T cells. Nat Immunol. 2007; 8: 1353-62.
52. Wolf D, Wolf AM, Rumpold Het al., The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005; 11: 8326-31.
53. Ghiringhelli F, Puig PE, Roux Set al., Tumour cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4(+)CD25(+) regulatory T cell proliferation. J Exp Med. 2005; 202: 919-29.
54. Coe D, Addey C, White Met al., The roles of antigen-specificity, responsiveness to transforming growth factor-beta and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells. Immunology. 2010; 131: 556-69.
55. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006; 238: 30-41.
56. Mizukami Y, Kono K, Kawaguchi Yet al., CCL17 and CCL22 chemokines within tumour microenvironment are related to accumulation of Foxp3(+) regulatory T cells in gastric cancer. Int J Cancer. 2008; 122: 2286-93.
57. Ruffini PA, Morandi P, Cabioglu Net al., Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer. 2007; 109: 2392-404.
58. Curiel TJ, Coukos G, Zou LHet al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-9.
59. Gobert M, Treilleux I, Bendriss-Vermare Net al., Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumours and lead to an adverse clinical outcome. Cancer Res. 2009; 69: 2000-9.
60. Chen WJ, Jin WW, Hardegen Net al., Conversion of peripheral CD4(+)CD25(-) naive T cells to CD4(+)CD25(+) regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198: 1875-86.
61. Coombes JL, Siddiqui KRR, Arancibia-Carcamo CVet al., A functionally specialized population of mucosal CD103(+) DCs induces Foxp3(+) regulatory T cells via a TGF-beta- and retinoic acid-dependent mechanism. J Exp Med. 2007; 204: 1757-64.
62. Yamazaki S, Bonito AJ, Spisek Ret al., Dendritic cells are specialized accessory cells along with TGF-beta for the differentiation of Foxp3(+) CD4(+) regulatory T cells from peripheral Foxp3(-) precursors. Blood. 2007; 110: 4293-302.
63. Zhou J, Ding T, Pan WDet al., Increased intratumoural regulatory T cells are related to intratumoural macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009; 125: 1640-8.
64. Dumitriu IE, Dunbar DR, Howie SEet al., Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Immunol. 2009; 182: 2795-807.
65. Liu VC, Wong LY, Jang Tet al., Tumour evasion of the immune system by converting CD4(+) CD25(-) T cells into CD4(+) CD25(+) T regulatory cells: role of tumour-derived TGF-beta. J Immunol. 2007; 178: 2883-92.
66. Kursar M, Bonhagen K, Fensterle Jet al., Regulatory CD4(+)CD25(+) T cells restrict memory CD8(+) T cell responses. J Exp Med. 2002; 196: 1585-92.
67. Larmonier N, Marron M, Zeng Yet al., Tumour-derived CD4(+) CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immun. 2007; 56: 48-59.
68. Leonie ST, Jocea MR, Machteld MTet al., Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol. 2005; 66: 222-30.
69. Misra N, Bayry J, Lacroix-Desmazes Set al., Cutting edge: human CD4(+)CD25(+) T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004; 172: 4676-80.
70. Trzonkowski P, Szmit E, Mysliwska Jet al., CD4(+)CD25(+) T regulatory cells inhibit cytotoxic activity of T CD8(+) and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 2004; 112: 258-67.
71. Zhao DM, Thornton AM, DiPaolo RJet al., Activated CD4(+)CD25(+) T cells selectively kill B lymphocytes. Blood. 2006; 107: 3925-32.
72. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002; 2: 151-61.
73. Lee DC, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immun. 2004; 53: 275-306.
74. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4(+) T cells triggers indoleamine 2, 3-dioxygenase activity in dendritic cells. J Immunol. 2004; 172: 4100-10.
75. Chung DJ, Rossi M, Romano Eet al., Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood. 2009; 114: 555-63.
76. Janssen EM, Lemmens EE, Wolfe Tet al., CD4(+) T cells are required for secondary expansion and memory in CD8(+) T lymphocytes. Nature. 2003; 421: 852-6.
77. Toes REM, Ossendorp F, Offringa Ret al., CD4 T cells and their role in antitumour immune responses. J Exp Med. 1999; 189: 753-6.
78. Zingoni A, Sornasse T, Cocks BGet al., Cross-talk between activated human NK cells and CD4(+) T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173: 3716-24.
79. Sakaguchi S, Yamaguchi T, Nomura Tet al., Regulatory T cells and immune tolerance. Cell. 2008; 133: 775-87.
80. Woo EY, Yeh H, Chu CSet al., Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002; 168: 4272-6.
81. Ratner A, Clark WR. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte mediated lysis. J Immunol. 1993; 150: 4303-14.
82. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002; 20: 323-70.
83. Waterhouse NJ, Sutton VR, Sedelies KAet al., Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. J Cell Biol. 2006; 173: 133-44.
84. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002; 2: 735-47.
85. Quezada SA, Peggs KS, Simpson TRet al., Limited tumour infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008; 205: 2125-38.
86. Zhou Q, Bucher C, Munger MEet al., Depletion of endogenous tumour-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009; 114: 3793-802.
87. Ghiringhelli F, Menard C, Terme Met al., CD4(+) CD25(+) regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005; 202: 1075-85.
88. Smyth MJ, Teng MWL, Swann Jet al., CD4(+)-CD25(+) T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006; 176: 1582-7.
89. Lapointe R, Bellemare-Pelletier A, Housseau Fet al., CD40-stimulated B lymphocytes pulsed with tumour antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003; 63: 2836-43.
90. Qin ZH, Richter G, Schuler Tet al., B cells inhibit induction of T cell-dependent tumour immunity. Nat Med. 1998; 4: 627-30.
91. Schultze JL, Grabbe S, Von MS. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 2004; 25: 659-64.
92. Lim HW, Hillsamer P, Banham HHet al., Cutting edge: direct suppression of B cells by CD4(+)CD25(+) regulatory T cells. J Immunol. 2005; 175: 4180-3.
93. Lewis CE, Pollard JW. Distinct role of macrophages in different tumour microenvironments. Cancer Res. 2006; 66: 605-12.
94. Takanami I, Takeuchi K, Kodaira S. Tumour-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999; 57: 138-42.
95. Klimp AH, Vries EGE, Scherphof GLet al., A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hema. 2002; 44: 143-61.
96. Forssell J, Oberg A, Henriksson MLet al., High macrophage infiltration along the tumour front correlates with improved survival in colon cancer. Clin Cancer Res. 2007; 13: 1472-9.
97. Li YW, Qiu SJ, Fan Jet al., Tumour-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol. 2009; 135: 439-49.
98. Galani IE, Wendel M, Stojanovic Aet al., Regulatory T cells control macrophage accumulation and activation in lymphoma. Int J Cancer. 2009; 127: 1131-40.
99. El Andaloussi A, Lesniak MS. Prolongation of survival following depletion of CD4(+)CD25(+) regulatory T cells in mice with experimental brain tumours. J Neurosurg. 2006; 105: 430-7.
100. Rudge G, Barrett SP, Scott Bet al., Infiltration of a mesothelioma by IFN-gamma-producing cells and tumour rejection after depletion of regulatory T cells. J Immunol. 2007; 178: 4089-96.
101. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumour immunity by removing CD25(+)CD4(+) T cells: a common basis between tumour immunity and autoimmunity. J Immunol. 1999; 163: 5211-8.
102. Viehl CT, Moore TT, Liyanage UKet al., Depletion of CD4(+)CD25(+) regulatory T cells promotes a tumour-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2006; 13: 1252-8.
103. Olsen E, Duvic M, Frankel Aet al., Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19: 376-88.
104. Ghiringhelli F, Larmonier N, Schmitt Eet al., CD4(+)CD25(+) regulatory T cells suppress tumour immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumours to be curative. Eur J Immunol. 2004; 34: 336-44.
105. Audia S, Nicolas A, Cathelin Det al., Increase of CD4(+)CD25(+) regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4(+)CD25(+) T lymphocytes. Clin Exp Immunol. 2007; 150: 523-30.
106. Ghiringhelli F, Menard C, Puig PEet al., Metronomic cyclophosphamide regimen selectively depletes CD4(+) CD25(+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immun. 2007; 56: 641-8.
107. Eklund JW, Kuzel TM. Denileukin diftitox: a concise clinical review. Expert Rev Anticanc. 2005; 5: 33-8.
108. Rasku MA, Clem AL, Telang Set al., Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008; 6: 12; doi:.
109. Sutmuller RPM, Van DLM, Van EAet al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumour therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001; 194: 823-32.
110. Cohen AD, Diab A, Perales MAet al., Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumour immunity. Cancer Res. 2006; 66: 4904-12.
111. Leach DR, Krummel MF, Allison JP. Enhancement of antitumour immunity by CTLA-4 blockade. Science. 1996; 271: 1734-6.
112. Yang YF, Zou JP, Mu Jet al., Enhanced induction of antitumour T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumour-bearing stages. Cancer Res. 1997; 57: 4036-41.
113. Dannull J, Su Z, Rizzieri Det al., Enhancement of vaccine-mediated antitumour immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115: 3623-33.
114. Klaqes K, Mayer CT, Lahl Ket al., Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010; 70: 7788-99.
115. Davila E, Kennedy R, Celis E. Generation of antitumour immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003; 63: 3281-8.
116. Hurwitz AA, Foster BA, Kwon EDet al., Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000; 60: 2444-8.
117. Hoffmann C, Stanke J, Kaufmann AMet al., Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumours in mice. J Immunother. 2010; 33: 136-45.
118. Sanderson K, Scotland R, Lee Pet al., Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005; 23: 741-50.